![]() | |
Supplier Name | MedChemExpress (MCE) |
Contact | sales |
Tel | 609-228-6898 |
Mobile | 609-228-6898 |
sales@medchemexpress.com; tech@medchemexpress.com | |
Website | https://www.medchemexpress.com/ |
Product Name | Odronextamab |
Synonyms | Odronextamab |
CAS | 1801338-64-6 |
EINECS | |
Chemical Formula | |
Molecular Weight | |
inchi | |
Package | 1 mg |
Price | Email to quote |
Descriptions | Odronextamab MedChemExpress (MCE) HY-P99038 99.50% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research. Odronextamab (1-10 nM, 48-96 h) at a low picomolar concentration, mediates cytotoxicity of all tested CD20-expressing lymphoma cells[2]. Odronextamab (0.4-1 mg/kg, administered via intraperitoneal injection, single dose) exhibits dose-dependent tumor-suppressive activity in a mouse tumor model[2]. Bispecific Human IgG4 kappa Human IgG4 (S228P) kappa, Isotype Control [1]. Rajat Bannerji, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet H [Content Brief] |
Last Update | 2025-04-01 14:45:47 |